Univariate and multivariate Cox proportional hazards models
| Variable before Glo . | Category . | PFS . | OS . | ||
|---|---|---|---|---|---|
| HR (univariate) . | HR (multivariate) . | HR (univariate) . | HR (multivariate) . | ||
| Age at Glo infusion | Continuous variable | P = .93 | — | P = .44 | — |
| Gender | Male/female | 0.99 (0.55-1.78; P = .97) | — | 0.89 (0.47-1.68; P = .71) | — |
| DLBCL, de novo | Yes vs no | 1.45 (0.77-2.72; P = .25) | — | 1.56 (0.78-3.11; P = .21) | — |
| HGBL with MYC and BCL2 and/or BCL6 rearrangements | Yes vs no | 1.65 (0.72-3.76; P = .24) | — | 1.60 (0.66 -3.88; P = .29) | — |
| Treatment lines before Glo | Continuous variable | P = .73 | — | P = .81 | — |
| Bendamustine within last 6 mos vs >6 mos/never | Yes vs no | 2.00 (1.11-3.62; P = .02) | 1.53 (0.79-2.97; P = .21) | 1.81 (0.95-3.47; P = .07) | — |
| CAR-T naive | Yes vs no | 1.97 (1.06-3.63; P = .03) | 1.57 (0.80-3.06; P = .19) | 2.17 (1.12-4.20; P = .02) | 1.62 (0.79-3.31; P = .19) |
| Refractoriness to last therapy | Yes vs no | 2.62 (1.26-5.48; P = .01) | 1.59 (0.69-3.67; P = .28) | 2.58 (1.12-5.92; P = .03) | 1.97 (0.79-4.90; P = .14) |
| Bulky disease (>7.5 cm) | Yes vs no | 2.78 (1.51-5.09; P = .0009) | 1.83 (0.93-3.58; P = .08) | 1.69 (0.87-3.26; P = .12) | — |
| LDH >400 U/L | Yes vs no | 1.89 (1.05-3.40; P = .03) | 1.83 (1.00-3.35; P = .05) | 2.10 (1.09-4.05; P = .03) | 1.98 (1.02-3.83; P = .04) |
| Variable before Glo . | Category . | PFS . | OS . | ||
|---|---|---|---|---|---|
| HR (univariate) . | HR (multivariate) . | HR (univariate) . | HR (multivariate) . | ||
| Age at Glo infusion | Continuous variable | P = .93 | — | P = .44 | — |
| Gender | Male/female | 0.99 (0.55-1.78; P = .97) | — | 0.89 (0.47-1.68; P = .71) | — |
| DLBCL, de novo | Yes vs no | 1.45 (0.77-2.72; P = .25) | — | 1.56 (0.78-3.11; P = .21) | — |
| HGBL with MYC and BCL2 and/or BCL6 rearrangements | Yes vs no | 1.65 (0.72-3.76; P = .24) | — | 1.60 (0.66 -3.88; P = .29) | — |
| Treatment lines before Glo | Continuous variable | P = .73 | — | P = .81 | — |
| Bendamustine within last 6 mos vs >6 mos/never | Yes vs no | 2.00 (1.11-3.62; P = .02) | 1.53 (0.79-2.97; P = .21) | 1.81 (0.95-3.47; P = .07) | — |
| CAR-T naive | Yes vs no | 1.97 (1.06-3.63; P = .03) | 1.57 (0.80-3.06; P = .19) | 2.17 (1.12-4.20; P = .02) | 1.62 (0.79-3.31; P = .19) |
| Refractoriness to last therapy | Yes vs no | 2.62 (1.26-5.48; P = .01) | 1.59 (0.69-3.67; P = .28) | 2.58 (1.12-5.92; P = .03) | 1.97 (0.79-4.90; P = .14) |
| Bulky disease (>7.5 cm) | Yes vs no | 2.78 (1.51-5.09; P = .0009) | 1.83 (0.93-3.58; P = .08) | 1.69 (0.87-3.26; P = .12) | — |
| LDH >400 U/L | Yes vs no | 1.89 (1.05-3.40; P = .03) | 1.83 (1.00-3.35; P = .05) | 2.10 (1.09-4.05; P = .03) | 1.98 (1.02-3.83; P = .04) |
Bold indicates significance. Only variables found to be significant in the univariate analysis were tested in the multivariate model; for variables not tested in the multivariate model. “—” is used to indicate unavailable data.
Glo, glofitamab.